Treatment of Chronic Urticaria When High-Dose H1-Antihistamine Updosing Has Failed
For patients with chronic urticaria who have not achieved complete symptom control despite a full course of high-dose 2nd-generation H1-antihistamine therapy, a structured next-line protocol defines the escalation path.
Previous treatment & failure condition
Updosing of a 2nd-generation H1-antihistamine — such as bilastine, cetirizine, desloratadine, ebastine, fexofenadine, levocetirizine, mizolastine, or rupatadine — up to 4-fold the standard dose did not achieve the required target: a continuous urticaria activity score (UAS) of 0 and a urticaria control test (UCT) score of 16.
Next-step approach (partial)
The protocol adds a targeted agent on top of the ongoing antihistamine. More than one option is available, with selection guided by the clinical situation. The full regimen — including the options, selection criteria, and monitoring — is in the complete protocol.
Treatment goal
Complete symptom control: a continuous urticaria activity score (UAS) of 0 and a urticaria control test (UCT) score of 16, alongside normalisation of quality of life.
References
DOI: 10.1111/all.70210
- We recommend adding on omalizumab for the treatment of patients with CU unresponsive to high doses of 2nd generation H1-antihistamines.
- We suggest using dupilumab as add-on treatment for patients with CSU unresponsive to high doses of 2nd generation H1-antihistamines.
- We suggest using remibrutinib as add-on treatment for patients with CSU unresponsive to high doses of 2nd generation H1-antihistamines.
- The goal of treatment is to treat the disease until it is gone, as efficiently and as safely as possible, aiming at a continuous complete control (consistently UAS = 0/UCT = 16) and a normalization of quality of life.